$INAB

IN8BIO, INC.

CIK:0001740279|SEC Filings

CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Operating expenses:
Research and development	$ 2,493	$ 2,487	$ 5,106	$ 5,459
General and administrative	2,442	2,714	5,095	5,402
Total operating expenses	4,935	5,201	10,201	10,861
Interest income	154	107	330	217
Loss from operations	(4,781)	(5,094)	(9,871)	(10,644)
Net loss	$ (4,781)	$ (5,094)	$ (9,871)	$ (10,644)
Net loss per share - basic	$ (0.25)	$ (1.24)	$ (0.51)	$ (3.65)
Net loss per share - diluted	$ (0.25)	$ (1.24)	$ (0.51)	$ (3.65)
Weighted-average number of shares used in computing net loss per common share, basic	19,467,091	4,119,153	19,468,087	2,920,157
Weighted-average number of shares used in computing net loss per common share, diluted	19,467,091	4,119,153	19,468,087	2,920,157

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Operating activities
Net loss	$ (9,871)	$ (10,644)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	500	511
Non-cash stock-based compensation	753	1,786
Amortization of finance lease right-of-use assets	170	526
Amortization of operating lease right-of-use assets	287	416
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	248	943
Other non-current assets	44	0
Accounts payable	135	(10)
Accrued expenses and other current liabilities	(872)	(412)
Short-term operating lease liabilities	348	225
Long-term operating lease liabilities	(434)	(390)
Net cash used in operating activities	(8,692)	(7,049)
Investing activities
Purchases of property and equipment	(242)	0
Net cash used in investing activities	(242)	0
Financing activities
Payment of issuance costs from December 2025 issuance of common stock	(77)	0
Proceeds from the issuance of common stock, net of issuance costs	0	7,352
Principal payments on financing leases	(169)	(459)
Net cash (used in) provided by financing activities	(246)	9,160
Net (decrease) increase in cash and restricted cash	(9,180)	2,111
Cash and restricted cash at beginning of period	27,312	11,386
Cash and restricted cash at end of period	18,132	13,497
Cash, end of period	17,956	13,226
Restricted cash, end of period	176	271
Cash and restricted cash, end of period	18,132	13,497
Supplemental disclosure of non-cash financing and investing activities:
Lease modification of operating lease right-of-use assets and liabilities	(349)	(1,287)
Series A & B Warrants
Financing activities
Proceeds from the exercise of Series C warrants, net of issuance costs	0	1,884
Series C Warrants
Financing activities
Proceeds from the exercise of Series C warrants, net of issuance costs	$ 0	$ 383

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets
Cash	$ 17,956	$ 27,092
Prepaid expenses and other current assets	540	788
Total Current Assets	18,496	27,880
Non-current assets
Property and equipment, net	1,600	1,858
Restricted cash	176	220
Right-of-use assets - finance leases	125	296
Right of use assets - operating leases	1,246	1,882
Other non-current assets	102	146
Total Non-Current Assets	3,249	4,402
Total Assets	21,745	32,282
Current liabilities
Accounts payable	444	309
Accrued expenses and other current liabilities	761	1,633
Short-term finance lease liability	126	295
Short-term operating lease liability	923	924
Total Current Liabilities	2,254	3,161
Long-term finance lease liability	0	0
Long-term operating lease liability	1,128	1,563
Total Non-Current Liabilities	1,128	1,563
Total Liabilities	3,382	4,724
Stockholders' Equity
Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; no shares issued and outstanding	0	0
Common stock, par value $0.0001 per share; 490,000,000 shares authorized at June 30, 2026 and December 31, 2025; 9,853,121 and 9,766,132 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	10	10
Additional paid-in capital	169,320	168,644
Accumulated deficit	(150,967)	(141,096)
Total Stockholders' Equity	18,363	27,558
Total Liabilities and Stockholders' Equity	$ 21,745	$ 32,282